- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Pacritinib is a new targeted drug for the treatment of bone marrow fibrosis with severe thrombocytopenia, and its management of side effects su...
Parkitinib may cause side effects such as diarrhea, nausea, and fatigue, which need to be alleviated through dietary adjustments, medication ...
Adagrasib is an oral inhibitor targeting KRASG12C mutations, suitable for second-line treatment of locally advanced or metastatic non-small cel...
Adagrasib is a KRASG12C inhibitor used to treat non-small cell lung cancer carrying KRASG12C mutations. 1. Usage and dosage (1) Standard ...
Adagrasib has clear contraindications for patients with severe liver injury and QTc prolongation, and strict risk assessment and monitoring of ...
As a KRASG12C inhibitor, common side effects such as nausea, vomiting, and fatigue of Adagrasib can be effectively managed through medication a...
Elacetrant is an oral selective estrogen receptor degrading agent (SERD), which is used to treat patients with ER positive, HER2 negative and E...
As a therapeutic drug for ER positive breast cancer, Elacetrant needs to focus on adverse reactions such as dyslipidemia, hepatotoxicity and ...
The common side effects such as nausea, joint pain, and fatigue during Elacestrant treatment can be effectively controlled through a graded man...
Elacetrant is an oral selective estrogen receptor degrading agent (SERD) for the treatment of advanced or metastatic breast cancer patients wit...
